 BEDFORD, Mass., April 07, 2021 GLOBE NEWSWIRE -- Homology Medicines, Inc. Nasdaq: FIXX, a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately 50.0 million, before deducting estimated offering expenses payable by Homology. Homology also granted the underwriter a 30-day option to purchase up to an additional 7.5 million of shares of its common stock. All of the shares in the offering are to be sold by Homology. 